Biogen Share Price (NASDAQ: BIIB)

$136.74

▲

0.38

(0.28%)

Last updated on August 27, 2025 at 1:29 AM IST

$₹

Check the interactive Biogen Stock chart to analyse performance

Biogen stock performance

as on August 27, 2025 at 1:29 AM IST

Today's Low:$135.49
Today's High:$136.74
$136.74
0.91%
Downside
Day's Volatility :0.91%
Upside
0.0%
52 Weeks Low:$110.04
52 Weeks High:$206.70
$136.74
19.53%
Downside
52 Weeks Volatility :46.77%
Upside
33.85%

Biogen Stock Returns

Period	Biogen Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	6.95%	4.5%	14.5%
6 Months	-2.92%	-7.9%	12.4%
1 Year	-32.91%	-12.3%	21.0%
3 Years	-30.81%	7.0%	76.7%

Biogen Inc. Key Stats

Check Biogen key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$136.36
Open	$135.49
Today's High	$136.74
Today's Low	$135.49
Market Capitalization	$20.0B
Today's Volume	$861.8K
52 Week High	$206.7
52 Week Low	$110.035
Revenue TTM	$10.0B
EBITDA	$3.2B
Earnings Per Share (EPS)	$10.45
PE Ratio	13.05
Profit Margin	15.31%
Quarterly Earnings Growth YOY	0.08%
Return On Equity TTM	9.13%

Stock Returns calculator for Biogen Stock including INR - Dollar returns

The Biogen stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Biogen investment value today

Current value as on today

₹71,275

Returns

₹28,725

(-28.72%)

Returns from Biogen Stock

₹33,252 (-33.25%)

Dollar Returns*

₹4,527 (+4.53%)

Indian investors sentiment towards Biogen Stock

-17%

Period: Jul 27, 2025 to Aug 26, 2025. Change in 30 Days versus previous period

Search interest for Biogen Stock from India on INDmoney has decreased by -17% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Biogen Stock

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential US Bluechip Equity Fund Direct Plan Growth	19452	-1770.72	0.67%
Motilal Oswal S&P 500 Index Fund Direct Growth	1184	-5.17	0.03%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	2085	-37.01	0.11%

Global Institutional Holdings in Biogen Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
11.79%
PRIMECAP Management Company
10.78%
BlackRock Inc
10.37%
State Street Corp
5.05%
Wellington Management Company LLP
3.27%
Geode Capital Management, LLC
2.62%

Analyst Recommendation on Biogen Stock

Rating

Trend

Buy

71%Buy

28%Hold

0%Sell

Based on 42 Wall street analysts offering stock ratings for Biogen(by analysts ranked 0 to 5 stars)

Biogen Share Price Target

What analysts predicted

Upside of 23.92%

Target:

$169.44

Current:

$136.74

Biogen share price target is $169.44, a slight Upside of 23.92% compared to current price of $136.74 as per analysts' prediction.

Biogen Stock Insights

Price Movement
In the last 7 days, BIIB stock has moved down by -1.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 2.43B → 2.64B (in $), with an average increase of 8.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 240.5M → 634.8M (in $), with an average increase of 62.1% per quarter
BIIB vs JNJ (1 yr)
In the last 1 year, Johnson & Johnson has given 8.4% return, outperforming this stock by 41.8%
BIIB vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 8.6% return, outperforming this stock by 39.9%
Price to Sales
ForBIIB every $1 of sales, investors are willing to pay $2.0, whereas for Johnson & Johnson, the investors are paying $4.7 for every $1 of sales.

Biogen Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$14.4B	↑ 6.88%
Net Income	$5.9B	↑ 32.9%
Net Profit Margin	40.96%	↑ 8.03%

	FY20	Y/Y Change
Revenue	$13.4B	↓ 6.49%
Net Income	$4.0B	↓ 32.06%
Net Profit Margin	29.76%	↓ 11.2%

	FY21	Y/Y Change
Revenue	$11.0B	↓ 18.32%
Net Income	$1.6B	↓ 61.1%
Net Profit Margin	14.17%	↓ 15.59%

	FY22	Y/Y Change
Revenue	$10.2B	↓ 7.36%
Net Income	$3.0B	↑ 95.8%
Net Profit Margin	29.95%	↑ 15.78%

	FY23	Y/Y Change
Revenue	$9.8B	↓ 3.32%
Net Income	$1.2B	↓ 61.89%
Net Profit Margin	11.81%	↓ 18.14%

	FY24	Y/Y Change
Revenue	$9.7B	↓ 1.62%
Net Income	$1.6B	↑ 40.57%
Net Profit Margin	16.87%	↑ 5.06%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$2.3B	↓ 4.01%
Net Income	$393.4M	↑ 57.55%
Net Profit Margin	17.18%	↑ 6.72%

	Q2 FY24	Q/Q Change
Revenue	$2.5B	↑ 7.61%
Net Income	$583.6M	↑ 48.35%
Net Profit Margin	23.68%	↑ 6.5%

	Q3 FY24	Q/Q Change
Revenue	$2.5B	↑ 0.04%
Net Income	$388.5M	↓ 33.43%
Net Profit Margin	15.76%	↓ 7.92%

	Q4 FY24	Q/Q Change
Revenue	$2.5B	↓ 0.45%
Net Income	$266.7M	↓ 31.35%
Net Profit Margin	10.86%	↓ 4.9%

	Q1 FY25	Q/Q Change
Revenue	$2.4B	↓ 0.97%
Net Income	$240.5M	↓ 9.82%
Net Profit Margin	9.89%	↓ 0.97%

	Q2 FY25	Q/Q Change
Revenue	$2.6B	↑ 8.82%
Net Income	$634.8M	↑ 163.95%
Net Profit Margin	24.0%	↑ 14.11%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$12.4B	↑ 6.75%

	FY20	Y/Y Change
Profit	$11.6B	↓ 6.3%

	FY21	Y/Y Change
Profit	$8.9B	↓ 23.78%

	FY22	Y/Y Change
Profit	$7.9B	↓ 11.01%

	FY23	Y/Y Change
Profit	$7.3B	↓ 7.51%

	FY24	Y/Y Change
Profit	$7.4B	↑ 0.87%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$1.7B	↓ 1.11%

	Q2 FY24	Q/Q Change
Profit	$1.9B	↑ 9.76%

	Q3 FY24	Q/Q Change
Profit	$1.8B	↓ 4.78%

	Q4 FY24	Q/Q Change
Profit	$1.9B	↑ 2.41%

	Q1 FY25	Q/Q Change
Profit	$1.8B	↓ 3.71%

	Q2 FY25	Q/Q Change
Profit	$2.0B	↑ 13.25%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$7.1B	↑ 14.4%
Investing Cash Flow	$470.5M	↓ 122.99%
Financing Cash Flow	$-5.9B	↑ 31.05%

	FY20	Y/Y Change
Operating Cash Flow	$4.2B	↓ 40.25%
Investing Cash Flow	$-608.6M	↓ 229.35%
Financing Cash Flow	$-5.3B	↓ 10.03%

	FY21	Y/Y Change
Operating Cash Flow	$3.6B	↓ 13.95%
Investing Cash Flow	$-563.7M	↓ 7.38%
Financing Cash Flow	$-2.1B	↓ 60.43%

	FY22	Y/Y Change
Operating Cash Flow	$1.4B	↓ 61.97%
Investing Cash Flow	$1.6B	↓ 379.69%
Financing Cash Flow	$-1.7B	↓ 16.24%

	FY23	Y/Y Change
Operating Cash Flow	$1.5B	↑ 11.77%
Investing Cash Flow	$-4.1B	↓ 360.12%
Financing Cash Flow	$149.3M	↓ 108.54%

	FY24	Y/Y Change
Operating Cash Flow	$2.9B	↑ 85.85%
Investing Cash Flow	$-799.2M	↓ 80.51%
Financing Cash Flow	$-683.5M	↓ 557.8%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$553.2M	↑ 4325.6%
Investing Cash Flow	$-66.0M	↓ 89.88%
Financing Cash Flow	$-439.6M	↓ 31.96%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$625.8M	↑ 13.12%
Investing Cash Flow	$466.5M	↓ 806.82%
Financing Cash Flow	$-245.2M	↓ 44.22%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$935.6M	↑ 49.5%
Investing Cash Flow	$-1.2B	↓ 353.18%
Financing Cash Flow	$-6.6M	↓ 97.31%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$760.9M	↓ 18.67%
Investing Cash Flow	$-18.6M	↓ 98.43%
Financing Cash Flow	$7.9M	↓ 219.7%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$259.3M	↓ 65.92%
Investing Cash Flow	$-47.3M	↑ 154.3%
Financing Cash Flow	$-23.0M	↓ 391.14%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$160.9M	↓ 37.95%
Investing Cash Flow	$-57.0M	↑ 20.51%
Financing Cash Flow	$-11.7M	↓ 49.13%

Biogen Technicals Summary

Sell

Neutral

Buy

Biogen is currently in a neutral trading position according to technical analysis indicators.

Biogen Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biogen Inc.	5.5%	-2.92%	-32.91%	-30.81%	-51.54%
Eli Lilly And Company	-13.94%	-24.0%	-27.14%	124.22%	371.98%
Johnson & Johnson	7.34%	9.4%	9.49%	9.46%	16.13%
Merck & Co. Inc.	1.52%	-4.52%	-26.75%	-2.57%	-0.36%
Novo Nordisk A/s	-18.38%	-37.11%	-58.34%	4.84%	71.11%
Abbvie Inc	10.06%	2.21%	5.91%	52.89%	120.34%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biogen Inc.	13.05	13.05	6.24	15.72	0.09	0.06	NA	120.29
Eli Lilly And Company	45.45	45.45	1.03	22.86	0.86	0.17	0.01	20.38
Johnson & Johnson	19.1	19.1	1.09	10.85	0.3	0.08	0.03	32.6
Merck & Co. Inc.	13.14	13.14	0.86	8.93	0.35	0.13	0.04	19.57
Novo Nordisk A/s	14.65	14.65	1.68	24.84	0.79	0.22	0.03	37.82
Abbvie Inc	99.81	99.81	0.44	11.97	1.13	0.09	0.03	-0.1

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biogen Inc.	Buy	$20.0B	-51.54%	13.05	15.31%
Eli Lilly And Company	Buy	$623.3B	371.98%	45.45	25.91%
Johnson & Johnson	Buy	$429.7B	16.13%	19.1	25.0%
Merck & Co. Inc.	Buy	$213.1B	-0.36%	13.14	25.79%
Novo Nordisk A/s	Buy	$247.0B	71.11%	14.65	35.61%
Abbvie Inc	Buy	$372.0B	120.34%	99.81	6.45%

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Organization	Biogen
Employees	7605
CEO	Mr. Christopher A. Viehbacher
Industry	Health Technology

Key Management of Biogen Inc.

Name	Title
Mr. Christopher A. Viehbacher	President, CEO & Director
Ms. Nicole Murphy	Executive VP and Head of Pharmaceutical Operations & Technology
Ms. Susan H. Alexander Esq.	Executive VP & Chief Legal Officer
Dr. Priya Singhal M.D., M.P.H.	Executive VP & Head of Development
Ms. Robin C. Kramer	Executive VP & CFO
Mr. Sean Godbout	Chief Accounting Officer & Global Corporate Controller
Mr. Tim Power M.B.A., Ph.D.	Head of Investor Relations
Mr. Adam Keeney Ph.D.	Executive VP & Head of Corporate Development
Dr. Ginger Gregory Ph.D.	Executive VP & Chief Human Resources Officer
Ms. Alisha A. Alaimo	President & Head of North America

Important FAQs about investing in BIIB Stock from India :

What is Biogen share price today?

Biogen share price today is $136.74 as on August 27, 2025 at 1:29 AM IST at the close of the market. Biogen share today touched a day high of $136.74 and a low of $135.49.

What is the 52 week high and 52 week low for Biogen share?

Biogen share touched a 52 week high of $206.70 and a 52 week low of $110.04. Biogen stock price today i.e. August 27, 2025 at 1:29 AM IST is closed at $136.74, lower by 33.85% versus the 52 week high.

How to invest in Biogen Stock (BIIB) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Biogen on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Biogen Shares that will get you 0.0110 shares as per Biogen share price of $136.74 per share as on August 27, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Biogen Stock (BIIB) from India?

Indian investors can start investing in Biogen (BIIB) shares with as little as ₹87.6525 or $1 (as of August 27, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹876.53 in Biogen stock (as per the Rupee-Dollar exchange rate as on August 27, 2025). Based on Biogen share’s latest price of $136.74 as on August 27, 2025 at 1:29 AM IST, you will get 0.0731 shares of Biogen. Learn more about fractional shares .

What are the returns that Biogen has given to Indian investors in the last 5 years?

Biogen stock has given -51.54% share price returns and 18.61% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?